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Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was fi rst reported from Wu-
han, China (1), and led to outbreaks of coronavirus 
disease (COVID-19), which was declared a pandemic 
by the World Health Organization on March 11, 2020. 
COVID-19 also has been affecting global economies, 
leading to several recessions (2). Japan experienced 
an outbreak of COVID-19 on the cruise ship Diamond 
Princess during the early stages of the epidemic in Feb-
ruary 2020 (3–5). The government of Japan prohibited 
entry into the country at the end of March, declaring a 
state of emergency in 7 prefectures on April 7, which 
became a nationwide policy on April 16. Against this 
backdrop, the Italian cruise ship Costa Atlantica had 
remained docked at Nagasaki City since January 2020 
for full maintenance. In April 2020, we identifi ed an 
outbreak of COVID-19 on this cruise ship.
COVID-19 spreads easily on cruise ships because 
of the “3 Cs”: crowded places, close-contact settings, 
and confi ned and enclosed spaces (6–9). Given the spe-
cialized setting of a cruise ship and its closed popula-
tion, a cruise ship can offer important insights about 
infectious disease epidemiology and transmission dy-
namics (10). How to manage an outbreak of COVID-19 
on a cruise ship is a matter of debate, especially in a re-
source-limited situation. To improve our understand-
ing of COVID-19 and prepare for outbreaks to come, 
studies of outbreaks on cruise ships are valuable. In this 
article we describe the epidemiology of the COVID-19 
outbreak on Costa Atlantica and approaches taken for 
managing and responding to this outbreak.
Methods
Setting
On April 19, 2020, offi cials of Costa Atlantica, which 
had been docked in Nagasaki City since January 
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In April 2020, a coronavirus disease (COVID-19) out-
break occurred on the cruise ship Costa Atlantica in Na-
gasaki,	 Japan.	Our	outbreak	 investigation	 included	623	
multinational crewmembers onboard on April 20. Median 
age	was	31	years;	 84%	were	men.	Each	crewmember	
was isolated or quarantined in a single room inside the 
ship, and monitoring of health status was supported by 
a remote health monitoring system. Crewmembers with 
more severe illness were hospitalized. The investigation 
found that the outbreak started in late March and peaked 
in	late	April,	resulting	in	149	laboratory-confi	rmed	and	107	
probable cases of infection with severe acute respiratory 
syndrome coronavirus 2. Six case-patients were hospi-
talized for COVID-19 pneumonia, including 1 in severe 
condition and 2 who required oxygen administration, but 
no deaths occurred. Although the virus can spread rapidly 
on a cruise ship, we describe how prompt isolation and 
quarantine combined with a sensitive syndromic surveil-
lance system can control a COVID-19 outbreak.
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2020, reported to Nagasaki City Public Health Cen-
ter that they had febrile crewmembers (11,12). No 
passengers were on board the ship. All 623 crew-
members had already completed their quarantine 
upon entry in Japan, but they had been asked to re-
frain from leaving the ship unless necessary as part 
of the public health policy to prevent the spread of 
COVID-19. Because of cruise ship employment con-
tracts, 56 crewmembers embarked during March 14–
April 3. Given the COVID-19 pandemic, the body 
temperature of all crewmembers had been checked 
daily since the end of February. Beginning March 
22, at the discretion of the cruise ship company, any 
crewmember with a body temperature >37.1°C was 
to be isolated in a single-passenger cabin room of the 
ship; beginning April 19, every nonessential worker 
was isolated or quarantined in a single-passenger 
cabin room. Essential workers were defined as crew-
members who were involved in the operation of the 
ship or in maintaining its operation and functional-
ity, such as the captain, engineers, and food prepara-
tion staff.
On April 20, we performed PCR assays for SARS-
CoV-2 for 4 crewmembers who had a body temper-
ature >37.1°C, resulting in 1 positive result. During 
April 21–25, all crewmembers underwent universal 
screening for infection by using loop-mediated iso-
thermal amplification (LAMP) for SARS-CoV-2. After 
the universal screening, each nonessential worker re-
mained isolated or quarantined in a single passenger 
cabin room. Even for those whose test results were 
positive, crewmembers with mild illness or without 
signs or symptoms remained on the ship, and the 
health status of all crewmembers was monitored dai-
ly. If clinically indicated, regardless of test results, ill 
persons were transported and admitted to hospitals 
in Nagasaki City at the discretion of the ship’s medi-
cal doctor.
Data Collection and Definitions
The study population included 623 crewmembers 
who were on board on April 20, 2020. The cruise ship 
company provided demographic and body tempera-
ture data (ship’s medical record) during March 14–
May 27 for all crewmembers on board. Demograph-
ic data included sex, date of birth, nationality, and 
occupation category. Before disembarkation from 
the ship, crewmembers also provided information 
regarding their smoking history, presence of any 
underlying disease, height and weight, daily body 
temperature, and clinical signs or symptoms dur-
ing April 28–May 29 by using a smartphone-based 
remote health monitoring system (13). Obesity, as 
a risk factor for severe COVID-19, was defined as 
a body mass index (BMI) >30 (14,15). Clinical signs 
and symptoms of COVID-19 were fever (body tem-
perature >37.5°C), cough, shortness of breath, nasal 
congestion, sore throat, nausea or vomiting, con-
junctival congestion, headache, fatigue, myalgia or 
arthralgia, diarrhea, olfactory dysfunction, and taste 
disorder (loss of taste), which are globally recog-
nized COVID-19 signs and symptoms (1,13,16–18). 
In managing this outbreak, the threshold value of a 
body temperature >37.1°C was applied on the basis 
of the cruise ship’s definition for illness and criteria 
for isolation precaution.
We defined laboratory-confirmed cases as ill-
ness in anyone with a positive test result for SARS-
CoV-2 by PCR or LAMP. We defined a probable 
case was defined as illness in anyone with signs or 
symptoms indicative of COVID-19 but with a nega-
tive test result (19). We divided the severity of CO-
VID-19 into 4 groups (20): severe pneumonia that 
required intubation or intensive care unit admis-
sion, moderate pneumonia that required oxygen 
administration, mild illness with COVID-19 signs 
or symptoms that did not require oxygen admin-
istration, and an asymptomatic condition without 
any clinical signs or symptoms. We performed chest 
radiographs or chest computed tomography scans 
only for those suspected of having pneumonia, such 
as prolonged fever or shortness of breath, and those 
who were hospitalized.
Testing Strategy
We confirmed SARS-CoV-2 infection by using PCR or 
LAMP. We conducted PCR according to the protocol 
recommended by Japan’s National Institute of Infec-
tious Diseases (21). LAMP is used for the detection of 
SARS-CoV-2 because of its fast turnaround time and 
acceptable levels of sensitivity and specificity (22–24). 
LAMP was conducted at the Institute of Tropical 
Medicine at Nagasaki University and Nagasaki Uni-
versity Hospital. Persons who tested positive were al-
lowed to disembark and travel back to their countries 
after negative test results were confirmed in subse-
quent tests and their signs or symptoms had resolved.
Data Analysis
We constructed an epidemic curve on the basis of 
illness onset date, which was based on a body tem-
perature >37.1°C according to the ship’s medical 
record or the smartphone-based health monitoring 
system; the onset date of body temperature >37.1°C 
was defined as the date when body temperature was 
>37.1°C with a body temperature <37.1°C until the 
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previous day. For the epidemic curve, we used body 
temperature >37.1°C for 2 reasons: first, it was the 
cruise ship’s definition for illness and criteria for 
isolation precaution; second, describing the epi-
demic curve based on the test results of SARS-CoV-2 
from the universal screening would not give an ac-
curate picture of this outbreak because screening 
was introduced ≈1 month after the beginning of the 
outbreak and would only detect infections prevalent 
at the time of screening.
In addition to monitoring such incident events, 
we monitored the daily prevalent numbers of crew-
members with a body temperature >37.1°C or signs 
or symptoms. To evaluate the spatial distribution 
of infection, we plotted on the ship’s map the cabin 
rooms of crewmembers with a body temperature 
>37.1°C before isolation. We noted the demographic 
characteristics of all crewmembers according to their 
test results and presence of signs or symptoms. We 
calculated attack rates for both laboratory-confirmed 
case-patients (laboratory-confirmed case-patients 
divided by all crewmembers) and with the addi-
tion of probable case-patients (laboratory-confirmed 
case-patients and probable case-patients divided 
by all crewmembers). We also plotted the clinical 
course of symptomatic crewmembers individually 
by calendar date.
We expressed continuous variables as medians 
and interquartile ranges (IQRs). We summarized 
categoric variables as numbers and proportions. 
We conducted statistical analyses by using Stata 16 
(StataCorp, https://www.stata.com).
Ethics
The governments of Nagasaki City and Nagasaki 
Prefecture conducted the surveillance of the COV-
ID-19 outbreak on this cruise ship during April 20–
May 29, 2020, under authorization by the Infectious 
Diseases Control Law. This study was approved 
by the Institutional Review Board at the Institute 
of Tropical Medicine at Nagasaki University (ap-
proval no. 200619242).
Results
Demographic Characteristics of the Crewmembers
Among the 623 crewmembers, the median age was 
31 years (IQR 26–40 years), and 84% (523/623) were 
men (Table 1). Thirty-six nations were represented 
by the crewmembers, including (in descending or-
der) the Philippines, India, Indonesia, and China; 
most (80%) crewmembers were from countries in 
Asia. Characteristic data were available for 593 
crewmembers. Of those, 25% (148/592) had a his-
tory of smoking, and 3.7% (22/593) had underlying 
diseases, including hypertension (2.0% [12/592]), di-
abetes (1.7% [10/592]), cardiovascular disease (0.2% 
[1/592]), and asthma (0.2% [1/592]). Median BMI 
was 24.1 (IQR 21.7–26.7), and 9.4% (49/523) crew-
members had obesity (BMI >30).
Overview of the COVID-19 Outbreak on the Cruise Ship
A body temperature >37.1°C was first detected in a 
crewmember on March 22, and afterwards, 5 other 
crewmembers had a body temperature >37.1°C dur-
ing March 24–27 (Figure 1, panel A). Their crew cabin 
rooms were not concentrated in a single area on the 
ship (Figure 2, panel A). However, all of these crew-
members belonged to the entertainment occupation 
group that boarded the cruise ship from several coun-
tries in Europe on March 18 and 19 (Appendix Figure 
1, https://wwwnc.cdc.gov/EID/article/27/9/20-
4596-App1.pdf). On April 2, another crewmember 
had a body temperature >37.1°C, and the number of 
persons with incident fever increased and peaked on 
April 28, decreasing thereafter (Figure 1, panel A). 
During March 22–May 29, a total of 211 (34%) had a 
body temperature >37.1°C. One crewmember who 
had a body temperature >37.1°C associated with 
cellulitis was excluded. Apart from the first wave 
of persons with a body temperature >37.1°C in late 
March, SARS-CoV-2 infection was distributed simi-
larly across sex, and age group, nationality, and oc-
cupation type (Appendix Figure 1). The crew cabin 
rooms of crewmembers who had a body temperature 
>37.1°C also were widely distributed throughout the 
ship (Figure 2, panel B). No information on the ven-
tilation system on the cruise ship was available. We 
compiled the daily number of crewmembers with a 
body temperature >37.1°C or with signs or symp-
toms; a peak occurred on April 28, after which the 
number gradually decreased until the end of May 
(Figure 1, panel B).
Among all 623 crewmembers, 149 cases were 
laboratory-confirmed and 107 probable case-patients 
who tested negative had clinical signs or symptoms 
indicative of COVID-19. Restricted to laboratory-
confirmed cases, the attack rate for infection was 24%. 
When probable cases were included, the attack rate 
was 41%.
Outbreak Control Measures and Management  
of Disembarkation
An emergency operations center was established in 
the prefecture office, and an onsite field response cen-
ter was set up in the harbor near the cruise ship (12). 
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Company staff stayed on board to communicate with 
both the ship and public health authorities, and com-
pany staff introduced interventions to the ship. On-
line meetings among company staff on board, the on-
site field response center, the emergency operations 
center, and Nagasaki University Hospital took place 
almost every morning. In the evening, online meet-
ings between Japan’s Ministry of Health, Labour and 
Welfare and the emergency operations center took 
place. Through these communication and coordination 
mechanisms, we were able to share information, make 
informed decisions jointly, and implement interven-
tions on the cruise ship.
Every nonessential worker had been separately 
isolated or quarantined in a single passenger cabin 
room and not allowed to leave his or her room since 
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Table 1. Selected characteristics of crewmembers on cruise ship where a coronavirus disease outbreak occurred, by SARS-CoV-2 
test result and symptomatic status, Nagasaki, Japan, 2020* 
Characteristic All crewmembers 
Test-positive, n = 149  Test-negative, n = 474 
Symptomatic Asymptomatic  Symptomatic Asymptomatic 
Total    623 (100) 96 (100) 53 (100)  107 (100) 367 (100) 
Age, y 
 Median (IQR) 31 (26–40) 32 (27–39) 32 (23–42)  29 (25–35) 31 (26–41) 
 Distribution 
  10–19 3 (0.5) 1 (1.0) 1 (1.9)  0 1 (0) 
  20–29 271 (43) 37 (39) 20 (38)  55 (51) 159 (43) 
  30–39 184 (30) 36 (38) 14 (26)  33 (31) 101 (28) 
  40–49 123 (20) 17 (18) 15 (28)  13 (12) 78 (21) 
  50–59 34 (5.5) 4 (4.2) 2 (3.8)  6 (5.6) 22 (6.0) 
  >60 8 (1.3) 1 (1.0) 1 (1.9)  0 6 (1.6) 
Sex 
 M 523 (84) 82 (85) 46 (87)  88 (82) 307 (84) 
 F 100 (16) 14 (15) 7 (13)  19 (18) 60 (16) 
Nationality 
 Philippines 206 (33) 35 (36) 6 (11)  40 (37) 125 (34) 
 India 104 (17) 16 (17) 14 (26)  16 (15) 58 (16) 
 Indonesia 84 (13) 10 (10) 13 (25)  13 (12) 48 (13) 
 China 82 (13) 14 (15) 7 (13)  13 (12) 48 (13) 
 Italy 40 (6.4) 5 (5.2) 3 (5.7)  6 (5.6) 26 (7.1) 
 Other 107 (17) 16 (17) 10 (19)  19 (18) 62 (17) 
Occupation category 
 Essential worker 
  Engine 75 (12) 6 (6.3) 11 (21)  10 (8.1) 48 (13) 
  Hotel 73 (12) 13 (14) 3 (5.7)  6 (5.0) 51 (14) 
  Deck 70 (11) 11 (11) 10 (19)  11 (9.4) 38 (10) 
 Nonessential worker 
  Restaurant 96 (15) 13 (14) 6 (11)  21 (20) 56 (15) 
  Galley 77 (12) 18 (19) 5 (9.4)  22 (21) 32 (8.7) 
  Housekeeping 72 (12) 8 (8.3) 7 (13)  7 (6.5) 50 (14) 
  Entertainment 49 (7.9) 8 (8.3) 6 (11)  13 (12) 22 (6.0) 
  Technician 21 (3.4) 4 (4.2) 2 (3.8)  3 (2.8) 12 (3.3) 
  Others 90 (14) 15 (16) 3 (5.7)  14 (13) 58 (16) 
Smoking history, n = 592† 
 Yes 148 (25) 20 (22) 13 (28)  36 (35) 79 (23) 
Underlying disease, n = 593†‡ 
 Any 22 (3.7) 5 (5.5) 2 (4.4)  2 (1.9) 13 (3.7) 
 Hypertension 12 (3.0) 2 (2.2) 1 (2.2)  0 9 (2.6) 
 Diabetes 10 (1.7) 1 (1.1) 1 (2.2)  0 8 (2.3) 
 Cardiovascular disease 1 (0.2) 1 (1.1) 0  0 0 
 Asthma 1 (0.2) 0 0  1 (1.0) 0 
BMI, n = 523† 
 Median (IQR) 24.1 (21.7–26.7) 23.6 (21.3–26.0) 24.7 (21.6–28.0)  23.9 (21.3–26.7) 24.1 (22.0–26.5) 
 Distribution 
  Underweight, BMI < 18.5 29 (5.5) 5 (6.2) 3 (7.5)  2 (2.0) 19 (6.3) 
  Normal, 18.5 < BMI < 25 278 (53) 45 (56) 18 (45)  58 (59) 157 (52) 
  Overweight, 25 < BMI < 30 167 (32) 22 (27) 15 (36)  27 (28) 103 (34) 
  Obese, BMI >30 49 (9.4) 9 (11) 4 (10)  11 (11) 25 (8.2) 
*Values are no. (%) except as indicated. Symptomatic was defined as having any clinical sign or symptom of coronavirus disease (i.e., fever (>37.5°C), 
cough, shortness of breath, nasal congestion, sore throat, nausea or vomiting, conjunctival congestion, headache, fatigue, myalgia or arthralgia, diarrhea, 
olfactory dysfunction, or taste disorder [loss of taste]). BMI, body mass index; IQR, interquartile range, SARS-CoV-2, severe acute respiratory coronavirus 
2. 
†Among crewmembers who entered data into the health monitoring system since its introduction on April 28, 2020. 
‡Two crewmembers had both hypertension and diabetes. 
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April 19. Essential workers who tested negative and 
had no signs or symptoms served meals or collected 
laundry for nonessential workers. When medically 
indicated, a nonessential worker was transported out 
of the room for medical care. To prevent secondary 
infection, several interventions were taken. Essential 
workers were provided with guidance and training 
for infection prevention on April 26. To ensure that 
the essential workers did not interact directly with 
isolated or quarantined crewmembers in their rooms, 
some interventions were put in place, such as distrib-
uting an individual thermometer to each crewmem-
ber on April 28 and streaming educational videos on 
COVID-19 infection prevention in the cabin rooms 
on April 29. To avoid missing the signs of disease 
progression and to be able to respond to critical pa-
tients in a timely manner, a field clinic was estab-
lished, along with provision of a vehicle equipped 
with a computed tomography scanner and a medical 
transportation system. A remote health monitoring 
system was developed and introduced to support the 
cruise ship from outside of the ship (17). After the ini-
tial universal screening in April, only essential work-
ers and medical personnel were reexamined when a 
sign or symptom indicative of COVID-19 was noted; 
reexaminations were limited in this way to prevent 
potential spread of the infection.
Starting May 3, those crewmembers who tested 
negative at universal screening were given prior-
ity to disembark; the ship’s medical doctor made 
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Figure 1. Number of incident 
cases of persons with body 
temperature >37.1°C	and	number	
of prevalent cases of persons 
with body temperature >37.1°C	
or any sign or symptom of 
coronavirus disease on a cruise 
ship, Nagasaki, Japan, March 
14–May	29,	2020.	A)	Number	
of persons with illness onset, 
by date. Crewmembers started 
disembarking	on	May	3.	B)	
Daily number of crewmembers 
who reported having a body 
temperature >37.1°C	or	
coronavirus disease signs or 
symptoms. Signs or symptoms 
other	than	fever:	cough,	
nasal congestion, sore throat, 
headache, olfactory dysfunction, 
taste disorder, conjunctival 
congestion, diarrhea, myalgia or 
arthralgia, fatigue, shortness of 
breath, and nausea or vomiting.
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the decision on the basis of the crewmember’s body 
temperature and signs or symptoms. Starting May 
14, crewmembers who tested positive were able to 
disembark and travel back to their countries of ori-
gin, provided that they had a subsequent negative 
test result. Through this predisembarkation testing 
policy, a total of 495 crewmembers were able to dis-
embark and leave Japan. On May 31, the cruise ship 
set sail for Manila, the Philippines, with the remain-
ing 126 essential workers, none of whom had a posi-
tive test result.
Clinical Outcomes
We compiled the clinical outcomes of all crewmembers 
and their signs or symptoms during their respective ob-
servation periods (Table 2). Among all crewmembers, 
0.2% (1/623) had severe pneumonia, 0.3% (2/623) had 
moderate pneumonia, 32% (200/623) had mild ill-
ness, and 67% (420/623) had no signs or symptoms. 
Among crewmembers with laboratory-confirmed cas-
es, 0.7% (1/149) had severe pneumonia, 1.3% (2/149) 
had moderate pneumonia, 62% (93/149) had mild 
illness, and 36% (53/149) had no signs or symptoms. 
Of the 11 crewmembers admitted to a hospital, 6 had 
COVID-19 pneumonia.
Clinical Course of Crewmembers Who Had Signs  
or Symptoms
During the observation period, 96 persons with lab-
oratory-confirmed cases and 107 with probable cases 
experienced signs or symptoms. The median number 
of symptomatic days among laboratory-confirmed 
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Figure 2. Initial cabin room 
locations of the crewmembers on 
cruise ship where a coronavirus 
disease outbreak occurred, 
Nagasaki, Japan, 2020. A) 
Red indicates distribution of 
crewmembers with onset of body 
temperature >37.1°C	during	March	
22–27. Green indicates cabin 
rooms of crewmembers who did 
not have a body temperature 
>37.1°C.	B)	Red	indicates	
distribution of crewmembers 
with onset of body temperature 
>37.1°C	during	March	22–April	19.	
Green indicates cabin rooms of 
crewmembers who did not have a 
body temperature >37.1°C.
COVID-19 on Cruise Ship, Nagasaki, Japan, 2020
case-patients was 4 days (IQR 1–8 days) (Appendix 
Table). Among laboratory-confirmed case-patients 
who were asymptomatic at the time of universal 
screening, 58 (52%) subsequently experienced signs 
or symptoms. Among 38% of the symptomatic crew-
members, symptoms were intermittent, or additional 
COVID-19 signs or symptoms appeared sporadically 
over time (Appendix Figure 2).
Discussion
We have described the key findings from the 
COVID-19 outbreak that occurred on a cruise ship 
with multinational crewmembers in Nagasaki City 
during April 20–May 29, 2020. Six crewmembers 
were hospitalized for COVID-19 pneumonia, 1 of 
whom had a severe case, but no deaths occurred. 
Our retrospective investigation revealed that the 
outbreak likely started in late March, with the infec-
tion introduced into this population from the enter-
tainment occupation group that boarded the ship, 
which then spread widely inside the ship, irrespec-
tive of occupational group, nationality, or crew cabin 
room location, resulting in 149 laboratory-confirmed 
cases and 107 probable cases. Because transmission 
of SARS-CoV-2 from presymptomatic or asymptom-
atic patients is known to occur (25), certain social ac-
tivities on the ship could have facilitated transmis-
sion which ultimately spread throughout the ship. 
The epidemic curve (Figure 1, panel A) shows that 
the number of incident case-patients with a body 
temperature >37.1°C peaked on April 28. The pe-
riod between the universal implementation of the 
quarantine policy (April 19) and the peak of onset 
(April 28) was longer than the expected incubation 
period (17,26). This fact might be attributable to sev-
eral reasons. For instance, before receiving training 
for infection prevention, essential workers might 
not have been able to sufficiently prevent infection 
transmission. Because an essential worker who was 
measuring body temperatures of isolated or quar-
antined crewmembers tested positive for SARS-
CoV-2 on May 3, we speculate that infection could 
have spread through any interactions during those 
measurements or through sharing of the thermom-
eters among the isolated or quarantined crewmem-
bers. These factors might have contributed to fur-
ther transmissions even after quarantine measures 
were enforced.
Management of the outbreak on Costa Atlantica 
was different from that observed on the Diamond 
Princess or other cruise ship outbreaks. The main 
difference was that the Costa Atlantica had only 
crewmembers whereas the Diamond Princess had 
both passengers and crewmembers. On Costa At-
lantica, because passenger cabin rooms inside the 
ship were empty, crewmembers could be isolated 
or quarantined inside the ship, which was not pos-
sible on the Diamond Princess or other cruise ship 
outbreaks with passengers. For the outbreak on the 
Diamond Princess, priority testing was given to 
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Table 2. Clinical outcomes of crewmembers on cruise ship where a coronavirus disease outbreak occurred, by SARS-CoV-2 test 
result, Nagasaki, Japan, 2020* 
Clinical outcome† All crewmembers Test-positive Test-negative 
Total 623 (100) 149 (100) 474 (100) 
Severe pneumonia 1 (0.2) 1 (0.7) 0 
Moderate pneumonia 2 (0.3) 2 (1.3) 0 
Mild illness 200 (32) 93 (62) 107 (23) 
Asymptomatic 420 (67) 53 (36) 367 (77) 
Fever (>37.5°C) 121 (19) 51 (34) 70 (15) 
Symptom, n = 593‡ 
 Cough 45 (7.6) 32 (23) 13 (2.9) 
 Nasal congestion 34 (5.7) 23 (17) 11 (2.4) 
 Sore throat 32 (5.4) 22 (16) 10 (2.2) 
 Headache 32 (5.4) 18 (13) 14 (3.1) 
 Olfactory dysfunction 31 (5.2) 25 (18) 6 (1.3) 
 Taste disorder 28 (4.7) 23 (17) 5 (1.1) 
 Conjunctival congestion 24 (4.1) 13 (9.5) 11 (2.4) 
 Diarrhea 16 (2.7) 12 (8.8) 4 (0.9) 
 Myalgia or arthralgia 13 (2.2) 11 (8.0) 2 (0.4) 
 Fatigue 11 (1.9) 7 (5.1) 4 (0.9) 
 Shortness of breath 8 (1.4) 7 (5.1) 1 (0.2) 
 Nausea or vomiting 5 (0.8) 4 (2.9) 1 (0.2) 
*Values are no. (%) except as indicated. SARS-CoV-2, severe acute respiratory coronavirus 2. 
†Severe pneumonia defined as illness requiring with intubation or intensive care unit admission; moderate pneumonia defined as illness requiring oxygen 
administration; mild illness defined as illness in patients who had coronavirus disease signs or symptoms without oxygen administration; asymptomatic, 
no clinical signs or symptoms. Body temperature data were obtained from the ship’s medical records and from the health monitoring system introduced by 
investigators on April 28, 2020. 
‡Among 593 crewmembers who entered data into the health monitoring system introduced by investigators; 137 crewmembers tested positive and 456 
tested negative for SARS-CoV-2. 
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the high-risk population. Passengers with positive 
test results for SARS-CoV-2 were transported to 
medical facilities, and their clinical courses fol-
lowed. For those passengers without positive test 
results, a 14-day health observation period was set 
before disembarking (27,28). One study suggested 
the possibility that evacuating all on board early 
would have prevented many on the Diamond Prin-
cess from becoming infected (29). Early evacuation 
of all crewmembers was thus initially considered in 
the Costa Atlantica outbreak. However, there were 
not enough medical facilities or accommodations 
to isolate or quarantine all crewmembers in the 
city, and preparing other isolation facilities would 
have required installing sewage systems and using 
communal toilets, which could promote transmis-
sion, making such options both impractical and of 
questionable value. Because we regarded the area 
inside the ship as contaminated, we developed and 
introduced a health monitoring system (13), aim-
ing to rapidly detect crewmembers requiring medi-
cal attention and to minimize the risk for second-
ary infection, which was an issue on the Diamond 
Princess (13,30). Debate is ongoing as to how to 
manage an outbreak of COVID-19 on a cruise ship, 
but we should take measures that are best suited 
for the particular context, especially in resource- 
limited situations.
As for clinical outcomes, we detected 3 crew-
members with moderate to severe pneumonia (2.0% 
of laboratory-confirmed cases and 1.2% of laboratory-
confirmed and probable cases); this proportion was 
lower than that noted in a previous report in China, in 
which 14% of case-patients had severe illness and 5% 
had critical illness (30). However, the population on 
the Costa Atlantica included only crewmembers, who 
were considerably younger and healthier by selection 
(i.e., healthy worker effect).
Among the laboratory-confirmed cases, we de-
termined 36% (42/149) to be in persons who were 
asymptomatic (25,31). In the Diamond Princess out-
break, the asymptomatic proportion was reported 
to be 55% (4), but after transfer to medical facilities, 
≈20% of asymptomatic subjects had onset of signs or 
symptoms (32,33). We were able to follow the clini-
cal courses of all laboratory-confirmed case-patients 
for >20 days, which prevented misclassification of 
presymptomatic cases as asymptomatic cases. We 
also obtained detailed clinical information after in-
troducing the health monitoring system, which had 
a high usage rate, enabling individual crewmem-
bers to report their signs or symptoms easily on a 
daily basis. These differences resulted in a lower 
proportion of asymptomatic cases in our study, 
which we think to be a more valid picture of the CO-
VID-19 severity spectrum.
Of note, we did not repeat LAMP and PCR tests 
for SARS-CoV-2 for nonessential workers in our test-
ing strategy. The main goal for our outbreak man-
agement was to prevent the spread of infection and 
to rapidly detect those persons who required medi-
cal attention (to provide them with appropriate and 
timely treatment); thus, repeat testing was not consid-
ered necessary as long as nonessential workers who 
were asymptomatic or had mild illness were isolated 
or quarantined. On the other hand, essential work-
ers were repeatedly tested because of the potential to 
spread the infection. Before the ship’s departure, 107 
probable cases were reported, which accounted for 
23% of crewmembers with negative test results. With 
limited frequency of testing, some interval-censored 
infections might have been missed, but with a sensi-
tive health monitoring system and an isolation and 
quarantine policy in place, we believe our operations 
were justifiable and effective.
Our study’s first limitation is that we might have 
underestimated the number of laboratory-confirmed 
cases because most crewmembers were only tested 
once. Second, the clinical signs or symptoms of the 
crewmembers before the introduction of the health 
monitoring system or after disembarkation could not 
be tracked, meaning additional symptomatic cases 
might have occurred.
In conclusion, we have described the epidemiol-
ogy, along with our management approach, of a CO-
VID-19 outbreak on a cruise ship with crewmembers 
isolated or quarantined inside the ship. Although 
SARS-CoV-2 can spread rapidly in closed settings, 
prompt isolation and quarantine and a sensitive sur-
veillance system using a remote health monitoring 
approach could successfully control a COVID-19 out-
break on a cruise ship and result in timely medical 
care for affected persons.
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